Dr. Weiren Huang | Genomic Data Analytics – The First Affiliated Hospital of Shenzhen University, Department of Urology, Shenzhen Institute of Translational Medicine, Shenzhen Second People’s Hospital | China
Dr. Weiren Huang is a pioneering researcher and principal investigator at The First Affiliated Hospital of Shenzhen University, working within the Department of Urology and the Shenzhen Institute of Translational Medicine. Recognized for his significant contributions to synthetic biology and its therapeutic applications in oncology, Dr. Huang has emerged as a national figure in precision gene circuit design and tumor-targeted interventions. As Deputy Director of the Synthetic Biology Committee under the China Medicinal Biotechnology Association and a committee member of several national scientific panels, he continues to drive innovation at the intersection of engineering biology and translational medicine. His work is transforming bladder cancer treatment through personalized, programmable therapeutics that hold promise for clinical implementation.
Professional Profile
Education
Dr. Huang earned his Ph.D. in a highly competitive program from Sun Yat-sen University, one of China’s premier research institutions. This rigorous academic foundation enabled him to integrate core knowledge in molecular biology, biomedical engineering, and translational medicine. His doctoral research set the stage for a career focused on genetic control systems and their application in oncology, especially through synthetic biology platforms. His educational background laid a solid groundwork for interdisciplinary research, bringing together urology, gene therapy, and bioengineering in a seamless and impactful way.
Experience
With extensive experience as Principal Investigator in national and regional research programs, Dr. Huang has led critical projects supported by the Ministry of Science and Technology of China, Shenzhen Science and Technology Innovation Commission, and Shenzhen Medical Research Fund. These initiatives address emerging clinical needs using genetic circuitry, tumor organoid modeling, and synthetic therapeutics. His notable leadership includes the National Key R&D Program project focused on microenvironment remodeling via gene circuits, where he directed a team on an ¥18.53 million venture that concluded successfully in 2024. As a research leader, he has managed multidisciplinary teams in high-throughput drug screening, cancer modeling, and cell-factory development, ensuring the translational potential of every scientific outcome.
Research Interest
Dr. Huang’s research interests center on synthetic biology, specifically the design and deployment of gene circuits for bladder cancer therapy. His approach involves integrating programmable gene expression modules with delivery vectors that selectively induce pyroptosis in tumor cells, ensuring minimal off-target effects. Another major focus is the use of tumor organoid chips to create personalized models that can evaluate drug sensitivity and gene circuit performance under near-physiological conditions. His work also touches on tumor microenvironment remodeling, examining how synthetic control systems can modulate immune responses and cellular signaling to enhance therapeutic outcomes. His unique angle lies in the development of cell factories and controllable gene expression systems that bridge lab innovation and clinical feasibility.
Awards
Dr. Huang has received significant recognition for his scientific contributions, including the prestigious Chinese Medical Science and Technology Award. He is also a recipient of the Guangdong Provincial Special Support Program for Distinguished Talents, placing him among the Top 100 Scholars of Guangdong. These accolades reflect not only his leadership in synthetic biology but also his broader influence on China’s biomedical innovation ecosystem. His ability to translate benchside discoveries into actionable therapies has earned him a reputation as a transformative scientist and clinician-researcher.
Publications
BCG therapy in bladder cancer and its tumor microenvironment interactions
Authors: Ni Jian, Lei Yu, Lijuan Ma, Binbin Zheng, Weiren Huang, Christopher Staley, Aaron Miller
Journal: Clinical Microbiology Reviews
Year: 2025
CD133⁺PD-L1⁺ cancer cells confer resistance to adoptively transferred engineered macrophage-based therapy in melanoma
Authors: Jiaojiao Xu, Zhe Li, Qinli Tong, Sihang Zhang, Jianchen Fang, Aihua Wu, Guoguang Wei, Chen Zhang, Sheng Yu, Binbin Zheng, et al.
Journal: Nature Communications
Year: 2025
Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules
Authors: Ziqiang Wang, Kun Li, Wei Chen, Xiaoxia Wang, Yikun Huang, Weiming Wang, Wanjun Wu, Zhiming Cai, Weiren Huang
Journal: Cellular and Molecular Life Sciences
Year: 2020